[ad_1]
London, May 03, 2022 (GLOBE NEWSWIRE) — Roots Analysis has announced the addition of “Subcutaneous Biologics, Technologies and Drug Delivery Systems Market (4th Edition), Industry Trends and Global Forecasts, 2022-2035″ report to its list of offerings.
The challenges associated with drug delivery via the parental route can be mitigated by if the candidates are administered through the subcutaneous route; the latter approach also enables self-medication by patients. Further, in order to ensure administration of biologics in large quantities, companies have developed a number of novel technology platforms. In this context, several subcutaneous self-administration drug delivery solutions, equipped with a range of user-friendly features, are already available in the market.
To order this 785+ page report, which features 615+ figures and 645+ tables, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
Key Market Insights
Over 120 biologics have been approved for administration via the subcutaneous route
Over 75% of the abovementioned therapeutics have been approved post 2001. Further, majority (~90%) of the approved subcutaneous biologics are either protein-based or antibody-based molecules. Of these, over 90% have been approved to be provided as monotherapies only.
Over 335 subcutaneous biologics are currently being evaluated in a clinical setting
Majority (~70%) of the aforementioned therapies are being evaluated in early stages of development (phase I, phase I / II and phase II). Of these, over 55% therapy candidates are reported to act via inhibiting the target molecule.
Success protocol framework can be used by developers to enhance the chances of success of their proprietary therapeutics
The proprietary framework evaluates top ten selling approved subcutaneous biologics, based on 5+ parameters, including disease indication burden, drug efficacy, geographical reach, global competition, patient compliance,…
[ad_2]
